| Literature DB >> 35436358 |
Rabish Kumar1, Meeta Singh1, Tanu Sagar1, M Bharanidharan1, Nita Khurana1, Vikas Kumar1, Ravi Meher1, Vikas Malhotra1, Ruchi Goel1, Sonal Saxena1, Jyoti Kumar1.
Abstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is associated with a wide range of disease patterns, ranging from mild to life-threatening pneumonia. COVID-19 can be associated with a suppressed immune response and/or hyperinflammatory state due to cytokine storm. Reduced immunity, combined with steroid usage to prevent cytokine storm along with various pre-existing co morbidities can prove to be a fertile ground for various secondary bacterial and fungal infection, including mucormycosis. Diagnosis of mucor is a challenging task given high negativity rate of various detection methods. While histopathology is considered the gold standard, the acquisition of necessary tissue biopsy specimens requires invasive procedures and is time consuming.Entities:
Keywords: COVID-19; Mucormycosis; liquid-based cytology
Year: 2022 PMID: 35436358 PMCID: PMC9111708 DOI: 10.1111/cyt.13131
Source DB: PubMed Journal: Cytopathology ISSN: 0956-5507 Impact factor: 1.286
Comparison of various diagnostic modalities for Mucor detection
| Sl. No | Age/Sex | Co‐morbidity | Site | Size of biopsy (cm) | LBC | Histopathology | Conventional cytology | Culture | KOH | Final |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 43/m | Diabetes | Lateral nasal wall | 1 × 0.8 ×0.8 | Neg | Neg | Neg | Neg | Neg | Neg |
| 2 | 50/f | Diabetes | Inferior turbinate | 0.8 × 0.6 ×0.6 |
|
| Neg |
| Neg | Pos |
| 3 | 50/f | Diabetes | Orbital apex | 2.8 × 2.6 × 2.6 |
|
|
|
|
| Pos |
| 4 | 50/m | Diabetes | Middle turbinate | 1 × 1 × 0.8 |
|
|
|
|
| Pos |
| 5 | 76/f | Diabetes | Inferior turbinate | 1.4 × 1.2×1 |
|
| Neg | Neg | Neg | Pos |
| 6 | 56/m | Leukaemia | Middle turbinate | 1.2 × 1.2 × 1 |
|
| Neg | Neg | Neg | Pos |
| 7 | 51/m | Diabetes | Inferior turbinate | 1.8 × 1.5 × 1.4 |
|
| Neg |
| Neg | Pos |
| 8 | 54/m | Diabetes | Inferior turbinate | 1.2 × 1.2 × 1 |
|
| Neg |
| Neg | Pos |
| 9 | 63/m | Diabetes | Middle turbinate | 2 × 1.8 × 1.8 |
|
| Neg | Neg | Neg | Pos |
| 10 | 52/m | Solid tumour | Middle turbinate | 1 × 1 × 0.8 |
|
| Neg |
| Neg | Pos |
| 11 | 75/f | Diabetes | Middle turbinate | 1.3 × 1.2 × 1.2 | Neg | Neg | Neg | Neg | Neg | Neg |
| 12 | 47/m | Diabetes | Middle turbinate | 2.2 × 1.8 × 1.8 |
|
| Neg |
| Neg | Pos |
| 13 | 38/m | Diabetes | Inferior turbinate | 2.2 × 2 × 1.8 | Neg | Neg |
|
|
| Pos (KOH, cul, conv) |
| 14 | 43/m | Solid tumour | Inferior turbinate | 2 × 2 × 2 |
| Neg | Neg | Neg |
| Pos (LBC, KOH) |
| 15 | 56/f | Diabetes | Inferior turbinate | 1.2 × 1 × 1 |
|
|
|
|
| Pos |
| 16 | 56/f | Tuberculosis | Palate | 1.6 × 1.5 × 1.2 |
|
|
|
|
| Pos |
| 17 | 52/f | Diabetes | Inferior turbinate | 1.8 × 1.6 × 1.5 | Neg |
| Neg | Neg | Neg | Pos |
| 18 | 45/f | Diabetes | Middle turbinate | 1.5 × 1.5 × 1.2 |
|
| Neg | Neg | Neg | Pos |
| 19 | 54/f | Diabetes | Middle turbinate | 1.8 × 1.8 × 1.2 |
|
| Neg |
| Neg | Pos |
| 20 | 63/m | Solid tumour | Middle turbinate | 2.5 × 2 × 2 |
|
|
|
| Neg | Pos |
| 21 | 58/f | Solid tumour | Lateral nasal wall | 1.8 × 1.4 × 1.4 | Neg | Neg | Neg | Neg | Neg | Neg |
| 22 | 46/m | Diabetes | Inferior turbinate | 2.4 × 2 × 2 | Neg | Neg | Neg | Neg | Neg | Neg |
| 23 | 50/m | Leukaemia | Middle turbinate | 1.8 × 1.6 × 1.6 |
|
|
|
| Neg | Pos |
| 24 | 34/m | Diabetes | Middle turbinate | 1.6 × 1.6 × 1.5 | Neg |
| Neg | Neg | Neg | Pos |
| 25 | 45/m | Diabetes | Inferior turbinate | 1.5 × 1.5 × 1.4 | Neg | Neg | Neg | Neg | Neg | Neg |
| 26 | 43/m | Diabetes | Middle turbinate | 1.4 × 1.2 × 1.2 | Neg | Neg | Neg |
| Neg | Pos (cul) |
| 27 | 47/f | Diabetes | Inferior turbinate | 0.8 × 0.8 × 0.8 |
|
|
|
|
| Pos |
| 28 | 56/m | Solid tumour | Lateral nasal wall | 1 × 0.8 × 0.8 | Neg | Neg |
| Neg | Neg | Pos (conv) |
| 29 | 47/f | Tuberculosis | Middle turbinate | 1.3 × 1.3 × 0.7 |
|
|
|
| Neg | Pos |
| 30 | 53/f | Diabetes | Orbitapex | 3 × 2.8 × 2.8 |
|
|
| Negative | Negative | Pos |
| 31 | 42/m | Diabetes | Middle turbinate | 1.7 × 1.5 × 1.2 | Neg | Neg | Neg | Neg |
| Pos (KOH) |
| 32 | 45/m | Leukaemia | Inferior turbinate | 1.5 × 1.4 × 1.4 |
|
|
|
| Neg | Pos |
| 33 | 37/f | Diabetes | Middle turbinate | 1.9 × 1.8 × 1.8 | Neg | Neg |
| Neg | Neg | Pos(con) |
| 34 | 65/m | Diabetes | Palate | 1.6 × 1.5 × 1.5 | Neg | Neg | Neg | Neg |
| Pos (KOH) |
Abbreviations: conv, conventional cytology; cul, culture; KOH, potassium hydroxide preparation; LBC, liquid‐based cytology; Sl.No, serial number.
Summary of various diagnostic modalities compared to the final diagnosis
| Final diagnosis | Total |
| |||
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Histopathology | Positive | 22 (100%) | 0 | 22 | 0.003 |
| Negative | 7 (58.3%) | 5 (41.7%) | 12 | ||
| LBC | Positive | 21 (100%) | 0 | 21 | 0.005 |
| Negative | 8 (61.5%) | 5 (38.5%) | 13 | ||
| Culture | Positive | 17 (100%) | 0 | 17 | 0.103 |
| Negative | 12 (70.6%) | 5 (29.4%) | 17 | ||
| Conventional cytology | Positive | 13 (100%) | 0 | 13 | 0.132 |
| Negative | 16 (76.2%) | 5 (23.8%) | 21 | ||
| KOH | Positive | 9 (100%) | 0 | 9 | 0.293 |
| Negative | 20 (80%) | 5 (20%) | 25 | ||
Abbreviations: KOH, potassium hydroxide preparation; LBC, liquid‐based cytology.
Figure 1Mucor hyphae on conventional smear with inflammatory cells in the background (Giemsa, 400×)
Figure 2(A) Mucor hyphae on BD SurePath ™ LBC smear (PAP, 100×; inset: PAP, 400×). (B) Mucor and Aspergillus hyphae in a case of mixed infection on BD SurePath™ LBC smear (PAP, 100×; inset: PAP, 400×)
Figure 3(A) Mucor hyphae on KOH preparation (400×). (B) Hyphae of Rhizopus species (lactophenol cotton blue [LPCB], 400×) with inset showing sporangium (LPCB, 400×)
Figure 4(A) Mucor hyphae on histopathology slide (HE 400×). (B,C) Mucor hyphae showing periodic anti‐Schiff (PAS) and silver methenamine positivity on histopathology slides (B: PAS, 400×; C: silver methenamine, 400×)
Comparison of positive predictive value, negative predictive value, sensitivity, and specificity of various modalities for Mucor detection
| Histopathology | LBC | Culture | Conventional cytology | KOH | |
|---|---|---|---|---|---|
| Sensitivity | 75.9% | 72.4% | 58.6% | 44.8% | 31% |
| Specificity | 100% | 100% | 100% | 100% | 100% |
| Positive predictive value | 100% | 100% | 100% | 100% | 100% |
| Negative predictive value | 41.7% | 38.4% | 29.4% | 23.8% | 20% |
Abbreviations: KOH, potassium hydroxide preparation; LBC, liquid‐based cytology.
Reports of mucormycosis in COVID‐19 patients in India
| Author | Number of cases | Age, sex | Risk factors | Site |
|---|---|---|---|---|
| Mehta et al | 1 | 60, M | Diabetes, Steroid | Nasal/Sinus, Orbit |
| Garg et al | 1 | 55, M | Diabetes, Steroid | Lung |
| Maini et al | 1 | 38, M | Steroid | Nasal/Sinus, Orbit |
| Saldanha et al | 1 | 32, M | Diabetes | Nasal/Sinus, Orbit |
| Revannavar et al | 1 | F | Diabetes | Nasal/Sinus, Orbit, brain |
| Sen et al | 6 | 46.2–73.9, M | Diabetes, Steroid (5) | Nasal/Sinus, Orbit, brain |
| Sarkar et al | 10 | 27–67, M/F = 8:2 | Diabetes, Steroid | Nasal/Sinus, Orbit, brain |
| Mishra et al | 10 | 37–78, M/F = 9:1 | Diabetes (8), Steroid (6) | Nasal/Sinus, Orbit, bone |
| Satish et al | 11 | 30–74, M/F = NR | Diabetes, Leukaemia (1) | Nasal/Sinus, Orbit |
| Moorthy et al | 17 | 39–73, M/F = 15:2 | Diabetes (15), Steroid (15) | Nasal/Sinus, Orbit, brain, bone |
| Sharma et al | 23 | Age NR, M/F = 21:2 | Diabetes (21), Steroid | Nasal/Sinus, Orbit, brain |